Benefit for Women's INOCA Eludes Familar Cardiovascular Meds in WARRIOR

You May Be Interested In:Boeing jet returns to US from China amid tariff war



(MedPage Today) — CHICAGO — The WARRIOR trial was not able to prove that intensive medical therapy reduced major adverse cardiovascular events (MACE) in women with ischemia but no obstructive disease.
For symptomatic patients with suspected…

share Paylaş facebook pinterest whatsapp x print

Similar Content

A female reporter holding two microphones takes notes on a pad
Opinion | ‘A Real Regulatory Dilemma Here’: What We Heard This Week
EMA Recommends Seladelpar for Primary Biliary Cholangitis
EMA Recommends Seladelpar for Primary Biliary Cholangitis
Severe Shigella Infections Increasing in Homeless Patients
Severe Shigella Infections Increasing in Homeless Patients
Allergy medications: Know your options
When do you need an alpha blocker?
A photo of a smartphone displaying the TikTok logo in front of the US flag.
Physician Content Creators Weigh In on TikTok’s Uncertain Future
Wounds in Fentanyl Users Exposed to Xylazine Described
Wounds in Fentanyl Users Exposed to Xylazine Described
The News Link | © 2025 | News